Dissolved and financials
CVR: 33249098
DKK 248,136
Gross profit
Net result: DKK 164,772
No owners listed
CVR · view owners
No management registered
CVR · view management
Dissolved
Ceased 25 May 2021
CVR · view overview
0 employees
Annual report 2019 · average
Director role ended: Thomas Nielsen
CVR · 25/05/2021
View the full event history
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was a Danish company of the type Aktieselskab based in Herlev, founded in 2010. The company has been dissolved on 25 May 2021. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. According to the 2019 annual report, the company had an average of 0 employees. In 2019, the company reported a gross profit of DKK 248,136 and a net result of DKK 164,772 compared with DKK 954,488 the year before. Equity in the 2019 report amounted to DKK 725,098.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 201901/01/2019 – 31/12/2019 | 248 t. | 165 t. | 1.1 mio. | 725 t. | 0 | |
| 201801/01/2018 – 31/12/2018 | 1.3 mio. | 954 t. | 8.8 mio. | 1.5 mio. | 0 | |
| 201701/01/2017 – 31/12/2017 | 2.9 mio. | 2 mio. | 7.6 mio. | 3 mio. | - | |
| 201601/01/2016 – 31/12/2016 | 16 mio. | 11.1 mio. | 70.1 mio. | 12 mio. | - | |
| 201501/01/2015 – 31/12/2015 | 60.4 mio. | 45.4 mio. | 49.8 mio. | 46 mio. | - | |
| 201401/01/2014 – 31/12/2014 | 42 mio. | 32.4 mio. | 66 mio. | 38.6 mio. | - | |
| 201301/01/2013 – 31/12/2013 | 4.2 mio. | 3.2 mio. | 96.7 mio. | 6.2 mio. | - | |
| 201201/01/2012 – 31/12/2012 | - | - | - | 500 t. | - |
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationNo. NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S is registered in the Danish CVR register with the status Dissolved and ceased on 25 May 2021.
The CVR number of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S is 33249098.
In 2019, NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S reported a gross profit of DKK 248,136.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S had an average of 0 employees in the 2019 financial year according to the annual report.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was founded on 18 October 2010.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi (industry code 721100).
As of May 25, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of May 25, 2021, Thomas Nielsen has stepped down as liquidator of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
On May 25, 2021, NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S exited liquidation.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was dissolved on May 25, 2021.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2019. Gross profit came to DKK 248,136, and the net result was DKK 164,772.
As of September 26, 2019, Thomas Nielsen has left the board of directors of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of September 26, 2019, Morten Asser Karsdal has left the board of directors of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of September 26, 2019, Thomas Nielsen is registered as liquidator of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of September 26, 2019, Claus Henrik Christiansen has stepped down as chairman of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of September 26, 2019, Jeppe Ragnar Andersen has stepped down as adm. dir of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
On September 26, 2019, NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S entered liquidation.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2018. Gross profit came to DKK 1,317,781, and the net result was DKK 954,488.
As of September 4, 2018, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of September 4, 2018, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2017. Gross profit came to DKK 2,860,959, and the net result was DKK 1,971,520.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2016. Gross profit came to DKK 15,990,692, and the net result was DKK 11,052,541.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2015. Gross profit came to DKK 60,441,747, and the net result was DKK 45,386,395.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2014. Gross profit came to DKK 41,981,534, and the net result was DKK 32,351,010.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2013. Gross profit came to DKK 4,172,733, and the net result was DKK 3,170,924.
As of January 1, 2014, Jeppe Ragnar Andersen is registered as adm. dir of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of January 1, 2014, Bente Juel Christiansen has stepped down as direktion of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 1, 2013, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has been appointed auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 1, 2013, ATHOS STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S has published its annual report for 2012.
As of February 6, 2013, ATHOS STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of February 6, 2013, Ankjær-Jensen & Partnere I/S, Statsautoriserede Revisorer has stepped down as auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 18, 2010, Ankjær-Jensen & Partnere I/S, Statsautoriserede Revisorer has been appointed auditor of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 18, 2010, Thomas Nielsen has joined the board of directors of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 18, 2010, Morten Asser Karsdal has joined the board of directors of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 18, 2010, Claus Henrik Christiansen is registered as chairman of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
As of October 18, 2010, Bente Juel Christiansen is registered as direktion of NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S.
NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S was founded on October 18, 2010.
